Differential action of bradykinin on intrarenal regional perfusion in the rat: Waning effect in the cortex and major impact in the medulla

Journal of Physiology

Volumn 587, Issue 15, 2009, Pages 3943-3953

  Badzyńska, Bozena ^a   Sadowski, Janusz ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; BRADYKININ; CALCIUM ACTIVATED POTASSIUM CHANNEL; CLOTRIMAZOLE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ICATIBANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL RAT; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PERFUSION; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; VASODILATATION; KIDNEY ARTERY; KIDNEY CORTICAL VASODILATATION; KIDNEY INNER MEDULLA; KIDNEY OUTER MEDULLA; MEAN ARTERIAL PRESSURE;

ANIMALS; BRADYKININ; CLOTRIMAZOLE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; MODELS, ANIMAL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; TRIAZOLES; VASODILATOR AGENTS;

EID: 68149100843     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2009.172007     Document Type: Article

References (47)

1. Baodzyńska B, Grzelec-Mojzesowicz M & Sadowski J (2003). Prostaglandins but not nitric oxide protect renal medullary perfusion in anaesthetised rats receiving angiotensin II. J Physiol 548, 875-880.
2. 2 on perfusion of rat renal cortex and medulla: interactions with the renin-angiotensin system. Exp Physiol 93, 1292-1302.
3. Bagate K, Develioglu L, Michel B, Grima M, Imbs JL & Barthelmebs M (1997). Renal vascular responses of bradykinin in the isolated rat kidney. Arch Mal Coeur Vaiss 90, 1131-1134.
4. Bergström G & Evans RG (2004). Mechanisms underlying the antihypertensive functions of the renal medulla. Acta Physiol Scand 181, 475-486.
5. Braun C, Ade M, Unger T, Van Der Woude FJ & Rohmeiss P (1997). Effects of bradykinin and icatibant on renal hemodynamics in conscious spontaneously hypertensive and normotensive rats. J Cardiovasc Pharmacol 30, 446-454.
6. Clements JA (2000). Tissue kallikrein-kinin system. In Handbook of Physiology, section 7, chap. 9, The Endocrine System, vol. III, Endocrine Regulation of Water and Electrolyte Balance, ed. Fray JCS & Goodman HM, pp. 333-376. Oxford University Press, N. York, Oxford.
7. Cowley AW (2008). Renal medullary oxidative stress, pressure-natriuresis, and hypertension. Hypertension 52, 777-786.
8. Dabisch PA, Kerut EK, Liles JT, Wien G, Smith M, Patterson M, Mccoul ED, Sears BW, Saenz R & Kadowitz PJ (2004). Responses to bradykinin are mediated by NO-independent mechanisms in the rat hindlimb vascular bed. Pharmacological Res 50, 575-584.
9. Drummond GB (2009). Reporting ethical matters in The Journal of Physiology: Standards and advice. J Physiol 587, 713-719
10. Edwards RM (1985). Response of isolated renal arterioles to acetylcholine, dopamine, and bradykinin. Am J Physiol 248, F183-F189.
11. Evans RG, Eppel GA, Anderson WP & Denton KM (2004). Mechanisms underlying the differential control of blood flow in the renal medulla and cortex. J Hypertens 22, 1439-1451.
12. Flamenbaum W, Gagnon J & Ramwell P (1979). Bradykinin-induced renal haemodynamic alterations: Renin and prostaglandin relationships. Am J Physiol Renal Physiol 237, F423-F440.
13. Fleming I & Busse R (2006). Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47, 629-633.
14. Fulton D, McGiff JC & Quilley J (1992). Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol 107, 722-725.
15. Gardes J, Baussant T, Cirvol P, Menard J & Alhenc-Gelas F (1990). Effect of bradykinin and kininogens in isolated rat kidney vasoconstricted by angiotensin II. Am J Physiol Renal Physiol 258, F1273-F1281.
16. Granger JP & Hall JE (1985). Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol Renal Physiol 248, F87-F92.
17. Hoagland KM, Maddox DA & Martin DS (1999 a). Intrarenal infusion of bradykinin elicits a pressor response in conscious rats via a B 2 -receptor mechanism. Can J Physiol Pharmacol 77, 563-570.
18. Hoagland KM, Maddox DA & Martin DS (1999 b). Bradykinin B 2 -receptors mediate the pressor and hemodynamic effects of intravenous bradykinin in conscious rats. J Auton Nerv Syst 75, 7-15.
19. Imig JD (2005). Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289, F496-F503.
20. Imig JD, Falck JR, Wei S & Capdevila JH (2001). Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vas Res 38, 247-255.
21. Kalyan A, Eppel GA, Anderson WP, Oliver JJ & Evans RG (2002). Renal medullary interstitial infusion is a flawed technique for examining vasodilator mechanisms in anesthetized rabbits. J Pharmacol Toxicol Methods 47, 153-159.
22. Katori M & Majima M (1996). Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol 70, 95-128.
23. Lu S, Roman RJ, Mattson DL & Cowley AW (1992). Renal medullary interstitial infusion of diltiazem alters sodium and water excretion in rats. Am J Physiol Regul Integr Comp Physiol 263, R1064-R1070.
24. Maier KG, Henderson L, Narayanan J, Alonso-Galicia M & Roman RJ (2000). Fluorescent HPLC assay for 20-HETE and other P-450 metabolites of arachidonic acid. Am J Physiol Heart Circ Physiol 279, H863-H871.
25. Matsuda H, Hayashi K, Arakawa K, Naitoh M, Kubota E, Honda M, Matsumoto A, Suzuki H, Yamamoto T, Kajiya F & Saruta T (1999). Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: Role of intrarenal bradykinin. J Am Soc Nephrol 10, 2272-2282.
26. Matsumura Y, Tadano K & Yamasaki T (1999). Renal haemodynamic and excretory responses to bradykinin in anaesthetized dogs. Clin Exp Pharmacol Physiol 26, 645-650.
27. Mattson DL (2003). Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol Renal Physiol 284, R13-R27.
28. Mattson DL & Cowley AW Jr (1993). Kinin action on renal papillary blood flow and sodium excretion. Hypertension 21, 961-965.
29. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F & Adam A (2005). The kallikrein-kinin system: Current and future pharmacological targets. J Pharmacol Sci 99, 6-38.
30. Nafz B, Berger K, Rösler C & Persson PB (1998). Kinins modulate the sodium-dependent autoregulation of medullary blood flow. Cardiovasc Res 40, 573-579.
31. Navar LG, Inscho EW, Majid DSA, Imig JD, Harrison-Bernard LM & Mitchell KD (1996). Paracrine regulation of the renal microcirculation. Physiol Rev 76, 425-536.
32. Pallone TL, Silldorff EP & Cheung JY (1998). Response of isolated rat descending vasa recta to bradykinin. Am J Physiol Heart Circ Physiol 43, H752-H759.
33. Patel A & Smith FG (2000). Renal haemodynamic effects of B 2 receptor agonist bradykinin and B 2 receptor antagonist HOE140 in conscious lambs. Exp Physiol 85, 811-817.
34. Pompermayer K, Assreuy J & Vieira MA (2002). Involvement of nitric oxide and potassium channels in the bradykinin-induced vasodilatation in the rat kidney perfused ex situ. Regul Pept 105, 155-162.
35. Rajapakse NW, Roman RJ, Falck JR, Oliver JJ & Evans RG (2004). Modulation of V 1 -receptor mediated renal vasoconstriction by epoxyeicosatrienoic acids. Am J Physiol Regul Integr Comp Physiol 287, R181-R187.
36. Ren Y, Garvin J & Carretero OA (2002). Mechanism involved in bradykinin-induced efferent arteriole dilation. Kidney Int 62, 544-549.
37. Roman RJ (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82, 131-185.
38. Roman RJ, Kaldunski ML, Scicli AG & Carretero OA (1988). Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol Renal Physiol 255, F690-F698.
39. Siragy HM, Jaffa AA & Margolius HS (1997). Bradykinin B 2 receptor modulates renal prostaglandin E 2 and nitric oxide. Hypertension 29, 757-762.
40. Tornel J, Madrid MI, Garcia-Salom M, Wirth KJ & Fenoy FJ (2000). Role of kinins in the control of renal papillary blood flow, pressure natriuresis, and arterial pressure. Circ Res 86, 589-595.
41. Vio CP, Loyola S & Velarde V (1992). Localization of components of the kallikrein-kinin system in the kidney: Relation to renal function. Hypertension 19, II10-II16.
42. Wang H, Garvin JL, Falck JR, Ren Y, Sankey SS & Carretero OA (2005). Glomerular cytochrome P-450 and cyclooxygenase metabolites regulate efferent arteriole resistance. Hypertension 46, 1175-1179.
43. Wang X, Trottier G & Loutzenhiser R (2003). Determinants of renal afferent arteriolar actions of bradykinin: Evidence that multiple pathways mediate responses attributed to EDHF. Am J Physiol Renal Physiol 285, F540-F549.
44. Webster ME & Gilmore JP (1964). Influence of kallidin-L0 on renal function. Am J Physiol 206, 714-718.
45. + current by clotrimazole in rat anterior pituitary GH3 cells. Neuropharmacology 38, 979-989.
46. Yu H, Carretero OA, Juncos LA & Garvin L (1998). Biphasic effect of bradykinin on rabbit afferent arterioles. Hypertension 32, 287-292.
47. Yun JCH, Gill JR Jr, Bartter FC, Kelly GD & Keiser HR (1982). Effect of bradykinin on renal function in dogs treated with indomethacin or propranolol. Renal Physiol 5, 31-43.